JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trugman, J. M.
Right arrow Articles by Wooten, G. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trugman, J. M.
Right arrow Articles by Wooten, G. F.

D1 dopamine agonist effects assessed in vivo with [14C]-2-deoxyglucose autoradiography

JM Trugman, WS Arnold, N Touchet and GF Wooten

Department of Neurology, University of Virginia Health Sciences Center, Charlottesville.

In rats with unilateral 6-hydroxydopamine (6-OHDA) lesions of the substantia nigra, the 2-deoxyglucose (2-DG) autoradiographic method of measuring regional cerebral glucose utilization (RCGU) was used to assess the effects of three systemically administered dopamine agonists: bromocriptine, pergolide and (+)-4-propyl-9- hydroxynaphoxazine (PHNO). Pergolide increased RCGU in the substantia nigra pars reticulata (SNr) ipsilateral to the lesion in a dose- dependent manner (0.04 mg/kg, up 52%; 0.4 mg/kg, up 111%), resulting in asymmetric glucose utilization on the dopamine-denervated and intact sides of the brain. Pretreatment with a selective D1 antagonist (SCH 23390, 0.5 mg/kg) blocked completely the RCGU increase elicited by pergolide (0.4 mg/kg) whereas pretreatment with a selective D2 antagonist (eticlopride, 1.0 mg/kg) only mildly attenuated this increase. The effect of drug treatments on RCGU in the entopeduncular nucleus (EP) paralleled that in the SNr. These results demonstrate that the RCGU increase in the EP and SNr after pergolide administration is dependent primarily on D1 receptor stimulation. Administration of bromocriptine and PHNO minimally altered RCGU in the ipsilateral EP and SNr and did not result in significant left/right RCGU asymmetry. Considered in the context of prior studies of selective D1 and D2 agonists, the results suggest that, in this model, the magnitude of the RCGU increase in the EP and SNr elicited by a dopamine agonist, above the modest effects produced by selective D2 stimulation, represents a measure of D1 agonist effect in vivo. The results support a nonselective D1/D2 stimulatory effect of pergolide (0.04-0.4 mg/kg) and a selective D2 action of both bromocriptine and PHNO.

Volume 250, Issue 3, pp. 1156-1160, 09/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
T. Hayakawa, M. C. J. Chang, S. I. Rapoport, and N. M. Appel
Selective Dopamine Receptor Stimulation Differentially Affects [3H]Arachidonic Acid Incorporation, a Surrogate Marker for Phospholipase A2-Mediated Neurotransmitter Signal Transduction, in a Rodent Model of Parkinson's Disease
J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 1074 - 1084.
[Abstract] [Full Text]

Home page
 J. Neurophysiol.Home page
K. J. Black, T. Hershey, M. H. Gado, and J. S. Perlmutter
Dopamine D1 Agonist Activates Temporal Lobe Structures in Primates
J Neurophysiol, July 1, 2000; 84(1): 549 - 557.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics.